Update on the use of deferasirox in the management of iron overload

Ali Taher1
Maria Domenica Cappellini2
1American University of Beirut, Beirut, Lebanon; 2Università di Milano, Policlinico Foundation IRCCS, Milan, Italy

Abstract: Regular blood transfusions as supportive care for patients with chronic anemia inevitably lead to iron overload as humans cannot actively remove excess iron. The cumulative effects of iron overload cause significant morbidity and mortality if not effectively treated with chelation therapy. Based on a comprehensive clinical development program, the once-daily, oral iron chelator deferasirox (Exjade®) is approved for the treatment of transfusional iron overload in adult and pediatric patients with various transfusion-dependent anemias, including β-thalassemia and the myelodysplastic syndromes. Deferasirox dose should be titrated for each individual patient based on transfusional iron intake, current iron burden and whether the goal is to decrease or maintain body iron levels. Doses of >30 mg/kg/day have been shown to be effective with a safety profile consistent with that observed at doses <30 mg/kg/day. Recent data have highlighted the ability of deferasirox to decrease cardiac iron levels and to prevent the accumulation of iron in the heart. The long-term efficacy and safety of deferasirox for up to 5 years of treatment have now been established. The availability of this effective and generally well-tolerated oral therapy represents a significant advance in the management of transfusional iron overload.

Keywords: deferasirox, Exjade, oral, iron chelation, iron overload, cardiac iron

Iron overload and chelation therapy

The human body has many mechanisms to absorb, transfer and store essential dietary iron, but none to excrete excess amounts. It is therefore inevitable that patients who undergo regular transfusion therapy to treat chronic anemia, such as those with β-thalassemia and the myelodysplastic syndromes (MDS), will develop iron overload, since every unit of blood contains approximately 200 mg of iron.1 Iron overload from transfusions may be exacerbated in some patients due to increased absorption of iron from the diet in response to ineffective erythropoiesis.2 Excess iron is deposited in parenchymal tissue, including the liver, heart and endocrine system, which leads to ongoing damage and, ultimately, to organ failure.

Iron chelation therapy is the only viable option for the treatment of transfusional iron overload and can prevent further cellular iron uptake and reduce levels of morbidity and mortality in regularly transfused patients.3,4 Deferoxamine (DFO; Desferal®) is the current standard of care for iron chelation therapy; however, as DFO is a large molecule with a short half-life (20 to 30 minutes), treatment requires a demanding regimen of slow continuous infusion over 8 to 12 hours, 5 to 7 days/week, which often results in poor compliance.5 The 3-times daily chelator deferiprone (Ferrirprox®) was the first oral chelator to reach market and it is currently available in a number of countries outside...
the USA and Canada for the second-line treatment of iron overload in adult patients with thalassemia major for whom DFO therapy is contraindicated or inadequate. The use of deferiprone has partly been restricted due to the occurrence of serious adverse events such as arthropathy (common), neutropenia and agranulocytosis (rare). Deferasirox (Exjade®), which became available in 2005, is an oral iron chelator that requires once-daily administration. It is currently approved in more than 90 countries for the treatment of chronic iron overload due to blood transfusions in pediatric and adult patients. Deferasirox has been evaluated in patients with a wide range of underlying anemias and a wealth of clinical data is now available. This review will provide an update on the use of deferasirox, primarily focusing on the recent long-term efficacy and safety data available from the extension studies, new analyses in patients with MDS, aplastic anemia (AA) and Diamond-Blackfan anemia (DBA), as well as updates on the effects of deferasirox on cardiac iron levels.

**Pharmacodynamics and pharmacokinetics of deferasirox**

**Chemistry and pharmacodynamic properties**

Deferasirox represents a new class of tridentate iron chelators, the N-substituted bis-hydroxyphenyl-triazoles. As a tridentate iron chelator, two molecules are required to form a stable complex with each iron (Fe³⁺) atom; the active molecule in deferasirox (ICL670) is highly lipophilic and 99% protein bound. Deferasirox has a high affinity and selectivity for Fe³⁺, which is approximately 14 and 21 orders of magnitude greater than its affinity for copper or zinc, respectively, which minimizes the potential for depletion of these trace elements. Animal models in several species, such as rats, gerbils and marmosets, demonstrated that deferasirox could efficiently and selectively mobilize iron from various tissues such as hepatocytes and cardiomyocytes, and could also promote iron excretion. Deferasirox is primarily metabolized by glucuronidation, with subsequent biliary excretion, and the deferasirox–iron complex is excreted in the feces.

**Pharmacokinetic properties**

Deferasirox is rapidly absorbed with a median t_{\text{max}} of 1 to 2 hours and a mean elimination half-life of 7 to 16 hours. The plasma concentration of deferasirox is proportional to the administered dose and plasma levels are maintained within the therapeutic range over 24 hours following once-daily administration. C_{\text{max}}, area-under-curve and half-life are similar in children (aged < 12 years) and adolescents (aged ≥ 12 years). Exposure to deferasirox is approximately 20% to 30% lower in children and adolescents than in adults, and is significantly lower in pediatric patients aged < 6 years compared with older pediatric patients. These factors may add an additional margin for tolerability and mean that pediatric patients require higher deferasirox doses than adults to achieve comparable efficacy. As the bioavailability of deferasirox is affected by food when consumed concomitantly, it is recommended that it is administered at least 30 minutes before eating.

**Efficacy of deferasirox**

**Introduction to deferasirox clinical trials**

The clinical efficacy of deferasirox has been thoroughly evaluated in patients with a wide range of transfusion-dependent anemias, including β-thalassemia, MDS, sickle cell disease (SCD), AA, DBA and other rare anemias. Five pivotal 1-year core studies were conducted in more than 1000 patients, while more than 900 patients were enrolled into subsequent extension studies and will receive treatment with deferasirox for up to a further 4 years. A wealth of data are also now available from a global program of additional studies, the largest of which include ESCALATOR (237 patients with β-thalassemia) and EPIC (1744 patients with various underlying anemias) (Table 1).

**Factors impacting on deferasirox efficacy**

The pivotal 1-year clinical studies demonstrated that the efficacy of deferasirox is dependent on both dose and ongoing transfusional iron intake. Although doses of 5 and 10 mg/kg/day are able to effectively remove iron they are generally insufficient to balance the iron uptake from regular blood transfusions. Doses of 20 to 30 mg/kg/day are able to maintain or reduce body iron burden depending on iron intake.

For most patients the recommended starting dose for deferasirox is 20 mg/kg/day, however this dose can be modified based on iron intake, current iron burden and a patient’s individual therapeutic goal (ie, whether the aim is to decrease or maintain body iron levels). Local prescribing information should be consulted. If necessary, deferasirox dose adjustments should be made in steps of 5 to 10 mg/kg/day every 3 to 6 months based on serum ferritin trends. Data from the ESCALATOR study suggested that a starting dose of 20 mg/kg/day is insufficient to decrease...
iron burden in heavily iron-overloaded patients, since dose increases above 20 mg/kg/day were required in 185/237 patients (78%) in the initial 1-year treatment period. Further dose increases were performed in 137/233 patients (59%) in the extension study, with increases to >30 mg/kg/day necessary in 112 patients; significant improvements in liver iron concentration (LIC) and serum ferritin were observed following these dose increases (Figure 1). The importance of timely and appropriate deferasirox dose adjustments to enable patients to achieve target serum ferritin levels has also been highlighted in the extension phases of the pivotal studies. Patients who initially received deferasirox 5/10 mg/kg/day had increases in serum ferritin during the core 1-year treatment period, however a gradual decline in iron burden to below baseline levels was observed once doses were subsequently increased. Figure 2 shows that doses of >20 mg/kg/day were necessary before patients were able to achieve a significant reduction in serum ferritin.28

The dosing approach used in the EPIC study accounted for iron intake as patients received initial deferasirox doses of 10 to 30 mg/kg/day depending on transfusion history, followed by dose titration in steps of 5 to 10 mg/kg/day every 3 months according to serum ferritin trends and safety markers. Changes in serum ferritin over the 1-year treatment period were reflective of dosage adjustments and mean iron intake (Figure 3). Significant decreases in serum ferritin were observed in each overall disease cohort (Table 2). These data from the EPIC study show that it is important to regularly monitor transfusional iron intake and serum ferritin levels during deferasirox therapy in order to optimize dosing.

Some patients will require escalation to >30 mg/kg/day to achieve therapeutic goals. A retrospective analysis of 228 patients who received deferasirox doses of >30 mg/kg/day in the extension studies and ESCALATOR demonstrated a significant reduction in median serum ferritin of 370 ng/mL (P < 0.001) from pre-dose-escalation to the time-of-analysis. These findings have important implications for patients who are heavily transfused and may require higher doses of deferasirox to reduce body iron burden.

**Efficacy across different underlying anemias**

**β-thalassemia major**

As complications of iron overload have been most widely studied in β-thalassemia major, this population was the primary focus of the deferasirox clinical trial program. The efficacy of deferasirox in this population was clearly demonstrated in the pivotal 1-year Phase III study (n = 296), where doses of 20 or 30 mg/kg/day provided dose-dependent changes in LIC and serum ferritin. These data were confirmed in several trials including EPIC, where

---

**Table 1** Trial design and key efficacy results from the ESCALATOR and EPIC studies

| Design | Population | Treatment | Key results |
|--------|------------|-----------|-------------|
| ESCALATOR: Open-label, 1 year<sup>24</sup> | Pediatric (≥2 years) and adult patients with β-thalassemia, MDS, DBA, SCD, AA and other rare anemias, n = 1744 | Deferasirox 20 mg/kg/day<sup>+</sup> (initial dose); dose adjustments in steps of 5–10 mg/kg/day based on serum ferritin and safety markers | • After 1 year: 57% of patients had treatment success (P < 0.001)<br>• Mean reduction in LIC: 3.4 mg Fe/g dw (P < 0.001)<br>• Proportion of patients with LIC < 7 mg Fe/g dw had risen from 9.9% at baseline to 26.2% in patients whose therapeutic goal was reduction, significant decrease in serum ferritin (–517 mg/mL; P < 0.001) |
| Subsequent extension study of at least 1 additional year<sup>25</sup> | All patients were previously unsuccessfully chelated with DFO and/or deferiprone | | |
| EPIC: Open-label, 1-year<sup>26</sup> | Pediatric (≥2 years) and adult patients with β-thalassemia, MDS, DBA, SCD, AA and other rare anemias, n = 237 (n = 233 in extension study) | Deferasirox 10–30 mg/kg/day (initial dose dependent on blood transfusion frequency); dose adjustments in steps of 5–10 every 3 months based on serum ferritin and safety markers | • At end of study: Proportion of patients with LIC < 7 mg Fe/g dw had risen to 44.4%. Further decreases in LIC and serum ferritin observed<br>• Significant reduction in serum ferritin from baseline in overall population (–264 ng/mL; P < 0.0001), reflective of dosage adjustments and ongoing iron intake<br>• Significant reduction in serum ferritin in each disease cohort |

**Abbreviations:** AA, aplastic anemia; DBA, Diamond-Blackfan anemia; DFO, deferoxamine; dw, dry weight; LIC, liver iron concentration; MDS, myelodysplastic syndromes; SCD, sickle cell disease.
937 patients with \(\beta\)-thalassemia major were enrolled and where a significant decrease in serum ferritin was observed after 1 year of deferasirox treatment (Table 2). In the ESCALATOR study, the proportion of \(\beta\)-thalassemia major patients with a LIC of \(<\)7 mg Fe/g dry weight (dw) increased from 9.9% at baseline, to 26.2% at 1 year and 44.4% at the end of study (median of 2.7 years). With appropriate dose adjustments, deferasirox continues to be effective over the long term in patients with \(\beta\)-thalassemia major, a finding that is supported by data from the extension studies over a median treatment period of 4.5 years (Figure 2).

Cardiac failure related to myocardial iron overload is the leading cause of death in regularly transfused patients with \(\beta\)-thalassemia major. Evidence for the ability of deferasirox to remove cardiac iron in patients with \(\beta\)-thalassemia major has been demonstrated in a number of studies. The largest of these was a substudy of EPIC, where deferasirox significantly improved myocardial T2* in patients with mild, moderate and severe myocardial siderosis (11.2 ms at baseline to 12.9 ms at 12 months; \(P < 0.0001\)) (Figure 4a). Left ventricular ejection fraction (LVEF) is a useful surrogate marker of cardiac function and is often used when evaluating the cardiac efficacy of an iron chelator. It was evaluated in the EPIC and ESCALATOR trials, which enrolled patients with baseline LVEF within the reference range for healthy adults (ie, \(\geq 56\%\)). LVEF, as measured by echocardiogram or cardiovascular magnetic resonance, was maintained at approximately 67% in the EPIC substudy, and improved significantly from 65.1% to 66.8% \((P = 0.0002)\) in the 1-year core ESCALATOR study. As well as removing iron from the heart, deferasirox may also prevent the accumulation of cardiac iron in iron-overloaded patients with normal cardiac iron levels (Figure 4b). This ability may potentially help in preventing future cardiac failure associated with myocardial siderosis in patients with \(\beta\)-thalassemia major.

**\(\beta\)-thalassemia intermedia**

Although patients with \(\beta\)-thalassemia intermedia are rarely transfused they are still at risk for developing iron overload due to increased intestinal iron absorption secondary to chronic anemia. Few studies with chelation therapy have been conducted in this population to date. However, data are emerging from small numbers of patients demonstrating that deferasirox can significantly decrease mean serum ferritin levels over 1 year of treatment (1356 to 914 ng/mL, \(P = 0.05\); 2030 to 1165 ng/mL, \(P = 0.02\) at doses of 10 to 20 mg/kg/day, respectively). A large prospective study is underway to fully evaluate the use of deferasirox in patients with thalassemia intermedia.

**Myelodysplastic syndromes**

Several studies have demonstrated the efficacy of deferasirox in maintaining or reducing body iron burden in patients
with MDS. As in the β-thalassemia population, deferasirox has dose-dependent efficacy in patients with MDS. The largest cohort of MDS patients (n = 341) ever assessed with iron chelation therapy were enrolled in the EPIC study; with appropriate dose adjustments, significant reductions in serum ferritin were noted after 1 year of deferasirox treatment (Table 2). Another large study in 176 heavily iron-overloaded MDS patients also showed decreases in serum ferritin. Preliminary data suggest that in addition to decreases in serum ferritin, improvements in hematological parameters can occur with deferasirox treatment in patients with MDS. Serum ferritin decreases during deferasirox treatment in patients with MDS have been shown to be associated with significant improvements in alanine aminotransferase (ALT), which is an indicator of hepatocellular injury. This is of importance given that liver dysfunction is a common complication in MDS, and prospective studies are warranted to further investigate this observation. MDS patients who are most likely to benefit from receiving chelation therapy are transfusion-dependent patients with lower-risk MDS (ie, Low or Int-1 International Prognostic Scoring System) and life expectancy >1 year, who have serum ferritin levels of >1000 ng/mL.

### Aplastic anemia, Diamond-Blackfan anemia, and other rare anemias

Patients with AA, DBA and other types of rare anemia often require blood transfusions as supportive therapy; however, the efficacy of chelation therapy has rarely been evaluated in these populations. A 1-year prospective Phase II trial with deferasirox included 30 patients with DBA and 22 patients with other rare anemias (including AA, α-thalassemia and sideroblastic anemia). Significant, dose-dependent effects on LIC and serum ferritin were observed in both groups over the 1-year treatment period. Patients with AA (n = 116), DBA (n = 14) and rare anemias (n = 43) were also enrolled in the EPIC study and significant overall reductions in serum ferritin from baseline to 1 year were observed in each of the disease groups (Table 2). As with the overall EPIC population, changes in serum ferritin were reflective of dose adjustments and iron intake during the study. A similar observation has been made based on interim data from 50 patients with AA in Korea, where significant reductions in mean LIC (P = 0.01) and serum ferritin (4185 to 2913 ng/mL, P < 0.01) were noted over the 1-year treatment period.

### Pediatric patients

The deferasirox clinical trial program included patients with a wide range of ages. Pediatric patients (aged 2 to 16 years) were well represented, comprising approximately 40% of all patients enrolled in the five pivotal studies. When used at appropriate doses for the degree of iron burden and the ongoing transfusional iron intake, deferasirox provides dose-dependent efficacy in pediatric patients for up to 5 years of treatment; these effects are similar to those observed in adult patients. Efficacy data have been confirmed by the large number of pediatric patients (n = 166) enrolled in the ESCALATOR study. In this heavily iron-overloaded pediatric population, significant decreases in mean LIC (−7.9 ± 8.7 mg Fe/g dw; P < 0.0001) and median serum
Table 2 Efficacy of deferasirox across various transfusion-dependent anemias: data from the EPIC trial

|                | β-thalassemia major (n = 937) | MDS (n = 341) | AA (n = 116) | Rare anemias (n = 43) | DBA (n = 14) |
|----------------|-------------------------------|---------------|--------------|-----------------------|-------------|
| Baseline, ng/mL* | 3157                          | 2730          | 3254         | 3161                  | 2289        |
| Change at 1 year, ng/mL* | −129                         | −253          | −964         | −832                  | −790        |
| P value         | 0.0007                        | 0.0019        | 0.0003       | 0.0275                | 0.0121      |
| Deferasirox dose, mg/kg/day** | 24.2 ± 5.6                  | 19.2 ± 5.4    | 17.6 ± 4.8    | 18.6 ± 5.6            | 21.0 ± 4.8  |

*Serum ferritin data are presented as median; **Dose data are presented as mean ± SD.

Abbreviations: AA, aplastic anemia; DBA, Diamond-Blackfan anemia; MDS, myelodysplastic syndromes.

Ferritin (−1126 ng/mL; P < 0.0001) were observed after a median of 2.8 years’ treatment.61

Effect of deferasirox on labile plasma iron
Excess iron in the blood saturates the iron-binding protein transferrin leading to non-transferrin-bound iron (NTBI) in the plasma. The cellular uptake of NTBI is uncontrolled, which can potentially lead to excessive accumulation of labile iron in tissues such as the heart, liver and endocrine system. This labile iron may be a key mediator of iron toxicity due to its ability to catalyze production of reactive oxygen species.62 Control of labile plasma iron (LPI) is therefore an important aim of chelation therapy. In the ESCALATOR study in patients with β-thalassemia, LPI levels were analyzed using an assay that measured iron-specific redox cycling capacity in the presence of low ascorbate concentrations.63 Redox reactions were detected by the oxidation of a fluorogenic probe to its fluorescent form, which allowed distinction of chelator-bound from chelator-free LPI. Data from this study demonstrated that daily trough levels of deferasirox are sufficient to maintain suppression of LPI (Figure 5).64 After 4 weeks of treatment and throughout the remainder of the 1-year treatment period, peak LPI levels observed just before deferasirox dosing were significantly decreased compared with baseline and remained within normal values. Similar sustained reductions in LPI with deferasirox have been observed in other disease cohorts, including MDS and AA.46,65,66 These findings support the concept that once-daily deferasirox therapy may decrease unregulated tissue iron loading and prevent further end-organ damage across various transfusion-dependent anemias.

Safety and tolerability of deferasirox
Deferasirox has a well-characterized and manageable safety profile in adult and pediatric patients as young as 2 years with various transfusion-dependent anemias.20–23 Most patients remain on deferasirox therapy and adverse events are not a common reason for study discontinuation; eg, only 74 of >1000 patients enrolled in the core clinical studies discontinued treatment with deferasirox due to the occurrence of adverse events.16,20–23 The most common drug-related adverse events reported during deferasirox treatment include transient, mild-to-moderate gastrointestinal disturbances (such as nausea, vomiting, abdominal pain and diarrhea) and skin rash; these events generally resolved spontaneously. For severe skin rash deferasirox should be interrupted until the rash has resolved; reintroduction at a lower dose with subsequent gradual escalation may then be considered in combination with a short period of oral steroid administration. Mild, non-progressive increases in serum creatinine, generally within the upper limit of normal (ULN), were observed in approximately one-third of patients in the pivotal 1-year clinical trials.16,20–23 Serum creatinine levels spontaneously returned to baseline in approximately two-thirds of patients who experienced these increases.67 There were no cases of moderate-to-severe renal insufficiency or renal failure and no patients permanently discontinued treatment due to creatinine increases. If there is an increase in serum creatinine beyond the age-appropriate ULN, deferasirox should be interrupted until levels have returned to the normal range. Treatment may then be restarted at a lower dose with gradual escalation. In the 1-year studies elevations of liver transaminases were reported in about 2% of patients; these were not dependent on dose and most patients had elevated baseline levels. Elevations greater than 10 × ULN, suggestive of hepatitis, were uncommon (0.3%).69 Following any unexplained, persistent, or progressive increases in serum transaminases, deferasirox treatment should be interrupted. Once the cause of the transaminase increases has been established or when levels have returned to normal, deferasirox may be restarted at a lower dose followed by gradual escalation.

The tolerability and safety profile of deferasirox in pediatric patients is similar to that observed in adults.29 As growth retardation and hypogonadism remain significant
Use of deferasirox in the management of iron overload

Dovepress

clinical problems in pediatric patients with β-thalassemia, it is important to note that growth and sexual development proceed normally during deferasirox therapy.24,29 In the ESCALATOR study, growth in pediatric patients was assessed based on height standard deviation score (h-SDS).68 At baseline, both boys and girls were initially smaller than the reference group across all ages (2 to <6, 6 to <12 and 12 to <16 years).24 Over the 1-year study period, the observed growth as evaluated by change from baseline in h-SDS showed growth improvements (>0.5 SDS) in 18.1% of patients, worsening in growth in 9.4% of patients, and no change from baseline in 72.5% of patients. In this population, girls aged 12 to <16 years showed a notable improvement in growth, with 66.7% of this cohort exhibiting a net increase in h-SDS (25% percentile or first quartile = –0.06).24

Long-term safety of deferasirox

Safety data with deferasirox has now been reported for up to 5 years of treatment (Table 3).28,60,69 Based on 472 patients with β-thalassemia who received deferasirox for a median of 4.5 years, 50 (10.6%) discontinued due to adverse events. The types of drug-related adverse events reported in the extension studies were similar to those reported in the initial 1-year treatment period, and the annual frequency generally decreased from year to year, ranging from 0% to 2.3% in years 2 to 5.29 In addition, there were no progressive increases in serum creatinine over longer-term deferasirox treatment.28 The long-term safety profile of deferasirox in diseases other than β-thalassemia is also available. Deferasirox has a well-characterized and manageable safety profile in SCD patients for up to 3.5 years of treatment and no progressive increases in serum creatinine were observed, demonstrating a favorable renal safety profile in these patients who are at risk of progressive renal disease.69 In MDS patients the most common adverse events are gastrointestinal disturbances and skin rash, similar to that observed with β-thalassemia patients.31

Drug interactions and post-marketing surveillance

Deferasirox inhibits CYP3A4 and CYP2C8 in vitro, therefore caution should be used when administering deferasirox with drugs metabolized by these enzymes. Deferasirox also inhibits CYP1A2, CYP2A6, CYP2D6, and CYP2C19, however the clinical significance of this is unknown. The concomitant use of deferasirox with potent UDP-glucuronosyltransferase inducers (eg, rifampicin, phenytoin, phenobarbital, ritonavir) may result in a decrease in deferasirox efficacy. The concomitant administration of deferasirox with other iron chelators, aluminum-containing antacid preparations, vitamin C or hydroxyurea has not been formally studied. There have been post-marketing reports of cytopenias (both spontaneous and from clinical trials) in patients treated with deferasirox, although all of these patients had either pre-existing hematologic disorders that are commonly associated with bone-marrow failure or complications of the underlying disease that are associated with cytopenias (eg, hypersplenism, sickle cell crisis, administration of chemotherapy). The relationship of these episodes to treatment with deferasirox is uncertain. As with the standard

Table 4 The effect of deferasirox on the mean cardiac T2* by baseline T2* in patients

| Time (months) | All patients | <10 ms | 10–20 ms |
|--------------|-------------|--------|----------|
| BL           | 14.6        | 11.2   | 7.4      |
| 12           | 17.4        | 12.9   | 8.2      |

*Pooled data from core and extension phases of 4 pivotal studies.

Figure 4 The effect of deferasirox on the mean cardiac T2* by baseline T2* in patients

A) with cardiac iron overload; B) with normal cardiac levels.

Table 3 Most common drug-related adverse events during a median 4.5-year treatment period with deferasirox in 472 patients with β-thalassemia

| Adverse event | Frequency, n (%) |
|---------------|-----------------|
| Abdominal pain| 62 (13.1)       |
| Nausea        | 55 (11.7)       |
| Diarrhea      | 40 (8.5)        |
| Vomiting      | 32 (6.8)        |
| Rash          | 23 (4.9)        |

*Pooled data from core and extension phases of 4 pivotal studies.
clinical management of such hematological disorders, blood counts should be monitored regularly. Post-marketing cases of acute renal failure, some with a fatal outcome, have also been reported. Most of the fatalities occurred in patients with severe complications related to the underlying disease (eg, patients with multiple co-morbidities who were in advanced stages of disease). It is therefore recommended that particular attention is given to monitoring serum creatinine levels in patients who have preexisting renal conditions, are elderly, have co-morbid conditions that may affect renal function, or are receiving medicinal products that depress renal function. There have also been post-marketing reports of hepatic failure, some with a fatal outcome, in patients treated with deferasirox. Most of these events occurred in patients with significant comorbidities, including liver cirrhosis and multi-organ failure. In addition, upper gastrointestinal ulceration and hemorrhage have been reported in some patients, including children and adolescents, receiving deferasirox. Physicians and patients should remain alert for signs and symptoms of these events and promptly initiate additional evaluation and treatment if a serious gastrointestinal adverse event is suspected.

Safety at low iron burden and high deferasirox doses

Maintaining serum ferritin levels below 1000 ng/mL is known to be associated with a reduced risk of iron-overload-related complications, such as heart failure, in patients with thalassemia. However, as the use of DFO has been associated with increased toxicity at low serum ferritin levels, it is of interest to assess the adverse event profile of patients enrolled in the deferasirox studies who achieved serum ferritin levels of <1000 ng/mL. An analysis of 174 patients demonstrated a similar safety profile to that observed in patients who did not achieve serum ferritin levels of <1000 ng/mL (n = 300). For example, the frequency of drug-related adverse events such as nausea (14.9% vs 12.7%), vomiting (8.0% vs 8.3%) and skin rash (5.2% vs 5.3%), were comparable. In addition, similar proportions of patients experienced increases in serum creatinine (14.9% vs 12.0%) and increases in ALT (6.9% vs 6.7%). These data suggest that when appropriately dosed, serum ferritin can be maintained at levels lower than 1000 ng/mL during deferasirox treatment without increases in the frequency or type of adverse event reported.

Data from patients who have received deferasirox doses of >30 mg/kg/day demonstrate that the safety profile is consistent with that observed at doses of <30 mg/kg/day. The most common drug-related adverse events were gastrointestinal events such as vomiting (n = 7, 3.1%), abdominal pain and nausea (n = 4, 1.8% for both).

Health economics of deferasirox

It is well established that compliance is a key factor determining outcome of iron chelation therapy, and
the route of administration has an impact on compliance. Due to the need for 8- to 12-hour infusions, 5 to 7 times per week, compliance with DFO is suboptimal, ranging from 59% to 78%. Poor compliance with treatment can lead to serious morbidities and have a significant impact on cost, for example complications of iron overload such as heart disease or diabetes may increase annual costs by US$40,000. As deferasirox is a once-daily oral treatment, improvements in compliance compared with DFO may lead to improved patient outcomes and lower treatment costs. These have been evaluated in a number of analyses.

Cost effectiveness of deferasirox

Two separate studies have compared the cost-effectiveness of DFO and deferasirox. In a US model, treatment with deferasirox resulted in an additional 4.5 quality adjusted life years (QALYs) per patient at an additional lifetime cost of US$126,018 per patient, translating into a cost-effectiveness ratio of US$28,255 per QALY gained. Deferasirox was also associated with lower net costs and higher QALYs than DFO in a UK-based model. In this analysis drug dose and cost was relayed to patient weight; for patients with a mean weight of 62 kg the incremental cost per QALY gained was £7775.

Effect of deferasirox on patient-reported outcomes

A number of deferasirox studies have evaluated patient-reported satisfaction, convenience and treatment preference, which may provide surrogate measures for treatment compliance, in patients with β-thalassemia, SCD and MDS. In one study, 97% of patients with β-thalassemia who switched from DFO to deferasirox reported that they preferred deferasirox to DFO, primarily due to convenience (37%), no injection-site soreness (25%) and less daily disruption (23%). Most patients were more satisfied with deferasirox therapy and found it to be more convenient than DFO (Figure 6). Similarly, another study found that 91% of 252 patients with β-thalassemia were ‘satisfied/very satisfied’ with treatment after 1 year compared with 23% at baseline (all patients had received DFO and/or deferiprone prior to initiation of deferasirox). Time lost for normal activities due to chelation therapy was substantially reduced with deferasirox treatment compared with prior treatments (from 28.8 hours/month at baseline to 3.0 hours/month after 1 year). Similar results have been observed in patients with SCD. Improvements in health-related quality of life, based on SF-36 domain scores (eg, physical functioning and general health), were observed during 1 year of deferasirox treatment in patients with β-thalassemia (n = 274), MDS (n = 168) and SCD (n = 50) who were enrolled in the EPIC study.

Conclusions and place in therapy

This article demonstrates the efficacy and safety profile of the oral iron chelator deferasirox, which has specific advantages over the other available chelators due to its formulation and route of administration. The large clinical development program including patients with various underlying anemias has demonstrated the ability of deferasirox to remove iron from the liver and heart. The efficacy of deferasirox is dependent on appropriate dosing according to current iron burden, ongoing transfusional iron intake and safety markers, and regular monitoring of these parameters is necessary to ensure dose adjustments are made in a timely manner. Recent data from a substudy of EPIC have confirmed the findings of previous smaller studies demonstrating that deferasirox can remove cardiac iron and maintain cardiac function based on LVEF.
can prevent the accumulation of cardiac iron, highlighting the importance of early intervention to aid in the prevention of future cardiac events resulting from myocardial siderosis. Data from several studies of up to 5 years’ duration provide support for the long-term efficacy of deferasirox in maintaining or reducing overall iron burden across a range of anemias. Deferasirox is well tolerated with a manageable safety profile over long-term treatment in both pediatric and adult patients. The frequency of treatment-related adverse events generally decreases over time; the most common adverse events reported are mild-to-moderate gastrointestinal disorders and skin rash. The safety profile is similar at doses above and below 30 mg/kg/day and at serum ferritin levels above and below 1000 ng/mL. Improved satisfaction with, and convenience of, deferasirox compared with DFO has also been shown, which may translate into improved compliance and subsequent cost savings. In conclusion, once-daily oral therapy with deferasirox provides a significant development in the treatment of iron overload in patients with transfusion-dependent anemias.

Disclosures
Ali Taher has received research grants and honoraria from Novartis Pharmaceuticals. Maria Domenica Cappellini has received honoraria from Novartis Pharmaceuticals, and is a member of their Speaker’s Bureau.

Acknowledgments
Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. We thank Andrew Jones, PhD for medical editorial assistance with this manuscript.

References
1. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115(2):239–252.
2. Pootrakul P, Kitcharoen K, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood. 1988;71(4):1124–1129.
3. Gabuttì V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26–36.
4. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574–578.
5. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739–761.
6. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of non compliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919–1929.
7. Ferriprox. Summary of Product Characteristics. Apotex; 1999.
8. Ceci A, Baard P, Felisi M, et al. The safety and effectiveness of deferasirox in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118(1):330–336.
9. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferoxamine. Blood. 2003;102(5):1583–1587.
10. Duffy-Warren F, Chesi A, Rigourd S, Frederick A. Exjade® (deferasirox). Basic Prescribing Information. URL http://www.exjade.com/index.jsp 2008.
11. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrioxin to ICL670. Curr Med Chem. 2003;10(12):1065–1076.
12. Steinhauser S, Heinz U, Bartholoma M, Weyhermüller T, Nick H, Hegetschweiler K. Complex formation of ICL670 and related ligands with FeIII and FeII. Eur J Inorg Chem. 2004;21:4177–4192.
13. Glickstein H, El BR, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracel lular labile iron and functional consequences. Blood. 2006;108(9):3195–3203.
14. Wood JC, Otto-Duessel M, Gonzales I, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res. 2006;148(5):272–280.
15. Nick H, Wong A, Acklin P, et al. ICL670A: preclinical profile. Adv Exp Med Biol. 2002;509:185–203.
16. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade®), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873–880.
17. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol. 2003;43(6):565–572.
18. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;10;361(9369):1597–1602.
19. Galanello R, Piga A, Cappellini MD, et al. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol. 2008;48(4):428–435.
20. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107(9):3455–3462.
21. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica. 2006;91(10):1343–1351.
22. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168–176.
23. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501–508.
24. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458–465.
25. Taher A, El-Beshlawy A, Elalfy M, et al. Deferasirox significantly reduces iron burden in heavily iron-overloaded patients with beta-thalassemia: 2.7 year results from the ESCALATOR study. Haematologica. 2009;94(Suppl 2):Abstract 209.
26. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: Prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2009. In press.
27. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood. 2008;111(2):583–587.
28. Cappellini MD, Galanello R, Piga A, et al. Efficacy and safety of deferasirox (Exjade®) with up to 4.5 years of treatment in patients with thalassemia major: a pooled analysis. Blood. 2008;112(11):Abstract 5411.
29. Piga A, Forni GL, Katamis A, et al. Deferasirox (Exjade®) in pediatric patients with β-thalassemia: update of 4.7-year efficacy and safety from extension studies. Blood. 2008;112(11):Abstract 3883.
30. Cappellini MD, Elalfy MS, Kattamis A, et al. Efficacy and safety of onecycle, oral iron chelator deferasirox (Exjade®) in a large group of regularly transfused patients with β-thalassaemia major. Blood. 2008;112(11):abstr 3878.

31. Gattermann N, Schmid M, Della Porta M, et al. Efficacy and safety of deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial. Blood. 2008;112(11):abstr 633.

32. Lee JW, Yoon SS, Shen ZX, et al. Iron chelation in regularly transfused patients with aplastic anemia: efficacy and safety results from the large deferasirox EPIC trial. Blood. 2008;112(11):abstr 439.

33. Porter JB, Lin KH, Habr D, Domokos G, Hmissi A, Thein SL. Deferasirox efficacy and safety for the treatment of transfusion-dependent iron overload in patients with a range of rare anemias. Blood. 2008;112(11):abstr 1419.

34. Porter JB, Forni GL, Beris P, et al. Efficacy and safety of 1 year’s treatment with deferasirox (Exjade®): assessment of regularly transfused patients with Diamond-Blackfan anemia enrolled in the EPIC study. Blood. 2008;112(11):abstr 1048.

35. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009. [Epub ahead of print].

36. Borgia-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193.

37. Pathe A, Taher A, Daar S. Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol. 2009. [Epub ahead of print].

38. Roghi A, Cassinerio E, Proto P, et al. The effect of deferasirox on myocardial iron overload and cardiac function: a prospective independent monocentric study using cardiovascular magnetic resonance T2* (MRI T2*). Haematologica. 2009;94(Suppl 2):abstr 762.

39. Wood J, Thompson A, Paley C, et al. Deferasirox reduces cardiac iron burden in chronically transfused β-thalassaemia patients with mild-to-moderate cardiac siderosis as demonstrated by MRI T2*. Haematologica. 2009;94(Suppl 2):abstr 763.

40. Eleftheriou P, Tanner M, Pennell D, Porter JB. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anemia; a subgroup analysis. Haematologica. 2006;91(Suppl 1):abstr 999.

41. Pennell D, Porter JB, Cappellini MD, et al. Efficacy and safety of deferasirox (Exjade®) in reducing cardiac iron in patients with β-thalassemia major: results from the cardiac subgroup of the EPIC trial. Blood. 2008;112(11):abstr 3873.

42. Pennell D, Dutcharitchan P, El-Beshlawy A, et al. Efficacy and safety of deferasirox (Exjade®) in preventing cardiac iron overload in β-thalassemia patients with normal baseline cardiac iron: results from the cardiac subgroup of the EPIC trial. Blood. 2008;112(11):abstr 3874.

43. Ladis V, Berdoussi H, Kattamis A. Treatment with deferasirox for non-transfusional iron overload in patients with thalassaemia intermedia. Haematologica. 2009;94(Suppl 2):abstr 1279.

44. Voskaridou E, Konstantimidou M, Douskou M, et al. Treatment with deferasirox effectively decreases iron burden in patients with thalassemia intermedia. Haematologica. 2009;94(Suppl 2):abstr 204.

45. Greenberg PL, Schiffer C, Koller CA, Glynos T, Paley C. Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of deferoxamine (DFX)/Exjade® therapy in a cohort of myelodysplastic patients. Blood. 2008;112(11):abstr 5083.

46. List AF, Baer MR, Steensma D, et al. Iron chelation with deferasirox (Exjade®) improves iron burden in patients with myelodysplastic syndrome (MDS). Blood. 2008;112(11):abstr 634.

47. Wimazal F, Nosslinger T, Baumgartner C, Sperr WR, Pfeilstocker M, Valent P. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. Eur J Clin Invest. 2009; 39:406-411.

48. Min YH, Kim HJ, Lee KH, et al. A multi-center, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R, MRI. Blood. 2008;112(11):abstr 3649.

49. Messa E, Cilloni D, Messa F, et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008;120(2):70–74.

50. Gattermann N, Schmid M, Guerci-Bresler A, et al. Reduction in serum ferritin (SF) is associated with improvement in liver transaminase levels during treatment with deferasirox (Exjade®) in iron overloaded patients with myelodysplastic syndromes (MDS). Leuk Res. 2009;33(Suppl 1):S140–S141 (abstr P140).

51. Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin. 2009;25(1):139–147.

52. Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981;304(6):319–324.

53. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83:385–386.

54. Gattermann N, Porter JB, Logue C.F, et al. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am. 2005;19(Suppl 1):18–25.

55. Vichinsky E, Coates T, Thompson AA, et al. Deferasirox (Exjade®), the once-daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): 3.5-year follow-up. Blood. 2008;112(11):abstr 1420.

56. Cancedo R, Olivato MC, Bruniera P, Chiattone C. Deferasirox for the treatment of transfusional iron overload in sickle cell anemia: a 1-yr prospective study. Haematologica. 2009;94(Suppl 2):abstr 210.

57. Voskaridou E, Douskou M, Plata E, et al. Treatment with deferasirox effectively decreases iron burden in patients with sickle cell syndromes. Haematologica. 2009;94(Suppl 2):abstr 215.

58. Rose C, Gattermann N, Glimm E, Rabault B. Deferasirox (Exjade, ICL670), the novel, once-daily oral iron chelator, is well tolerated and effective in treating transfusional iron overload in patients with a range of rare anemias. Haematologica. 2006;91(Suppl 1):abstr 22.

59. Tchernia G, Vichinsky E, Jeng M, et al. The once-daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in Diamond-Blackfan anaemia patients. Haematologica. 2005;90(Suppl 2):abstr 192.

60. Piga A, Kebaili K, Galanello R, et al. Cumulative efficacy and safety of 5-year deferasirox (Exjade®) treatment in pediatric patients with thalassemia major: a Phase II multicenter prospective trial. Blood. 2008;112(11):abstr 5413.

61. Taher A, Al Jefri A, Elalfy MS, et al. Deferasirox (Exjade®) treatment in pediatric β-thalassaemia patients with high iron burden: 2.8 years results from ESCALATOR trial. Blood. 2008;112(11):abstr 3879.

62. Kruszewski M. The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol. 2004;51(2):471–480.

63. Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102:2670–2677.

64. Daar S, Pathe A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia. Eur J Haematol. 2009;82(5):454–457.

65. Porter JB, Cappellini MD, El-Beshlawy A, et al. Effect of deferasirox (Exjade®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-year EPIC trial. Blood. 2008;112(11):abstr 3881.

66. Ghetti H, Fibach E, Merkel D, et al. Decrease in intra- and extra-cellular free iron species and oxidative stress parameters and increase in serum and urinary hepcidin during treatment with deferasirox in iron-loaded patients with MDS. Haematologica. 2009;94(Suppl 2):abstr 797.
67. Bennett W, Ponticelli C, Piga A, Kattamis A, Glimm E, Ford J. Summary of long-term renal safety data in transfused patients with secondary iron overload receiving deferexirox (Exjade®). Blood. 2006;108(11):abstr 3816.

68. Kuczynsks RJ, Ogden CL, Grummer-Strawln LM, et al. CDC growth charts: United States. Adv Data. 2000;(314):1–27.

69. Vichinsky E, Coates T, Thompson A, et al. Safety and efficacy of iron chelation therapy with deferexirox in patients with sickle cell disease (SCD): 3.5-year follow-up. Haematologica. 2009;94(Suppl 2):abstr 200.

70. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferexirox infusions. N Engl J Med. 1986;314(14):869–873.

71. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73(3):403–409.

72. Porter JB, Piga A, Cohen A, Ford JM, Bodner J, Cappellini MD. Assessment of safety in patients receiving longer-term iron chelation therapy with deferexirox who had achieved serum ferritin levels of <1000 ng/mL during the study course. Haematologica. 2009;94(Suppl 2):abstr 199.

73. Porter JB, Piga A, Cohen A, et al. Safety of deferexirox (Exjade®) in patients with transfusion-dependent anemias and iron overload who achieve serum ferritin levels <1000 ng/mL during long-term treatment. Blood. 2008;112(11):abstr 5423.

74. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferexeraxine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567–573.

75. Renfroe JL, Forbes P, Braunstein J, Neufeld EJ. Relationship of transfusion and iron-related complications to cost of care in thalassemia. Blood. 2005;106(11):abstr 2240.

76. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferexirox versus infusional deferexirox in transfusion-dependent thalassaemia patients. US healthcare system perspective. Pharmacoeconomics. 2007;25(4):329–342.

77. Kurok J, Tolley K, Oyee J, Jewitt K, Ossa A, Akehurst R. Cost-utility analysis of deferexirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin. 2008;24(6):1609–1621.

78. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferexirox or deferexirox for iron overload in patients with thalassemia. Clin Ther. 2007;29(5):909–917.

79. Porter JB, Bowden D, Ganser A, et al. Satisfaction and adherence significantly improves in patients with thalassemia and myelodysplastic syndromes treated with deferexirox (Exjade®). Blood. 2008;112(11):abstr 1306.

80. Taher A, Jefri A, Elafi M, et al. Improved treatment satisfaction and convenience with deferexirox in iron-overloaded patients with thalassemia: Results from ESCALATOR trial. Haematologica. 2008;93(Suppl 1):abstr 799.

81. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferexirox (Exjade®, ICL670) versus deferexirox in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label Phase II trial. Acta Haematol. 2008;119(3):133–141.

82. Porter JB, Bowden D, Ganser A, et al. Improved health-related quality of life in patients with hematological disorders receiving deferexirox (Exjade®). Blood. 2008;112(11):abstr 1307.

83. Aldouri MA, Wonke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in beta-thalassemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol. 1990;84(3):113–117.

84. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous deferexirox: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348–355.

85. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferexirox infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95(4):1229–1236.